The Food and Drug Administration's role in establishing and maintaining safeguards for contact lenses and contact lens care products.
Malvina B. Eydelman,M. Tarver,Tina Kiang,Kesia Y Alexander,J. Hutter
DOI: https://doi.org/10.1097/ICL.0b013e318258e694
2012-11-01
Abstract:In the United States, contact lenses (CLs) and CL care products are considered to be medical devices and, as such, are regulated by the Food and Drug Administration (FDA). The FDA is charged with protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biologic products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation, including regulating tobacco products. The Center for Devices and Radiological Health (CDRH), one of FDA’s six product centers, is responsible for ensuring that safe and effective devices reach the market as quickly as possible while monitoring devices and radiologic products currently on the market for continued safety and effectiveness. Medical devices are classified by risk as classes I, II, or III, with class III devices having the highest level of risk. All rigid gas permeable (RGP) CLs, daily wear soft CLs, and contact lens care products are class II devices, requiring 510(k) application submission to the FDA for marketing clearance. The 510(k) application must contain adequate information, in the form of preclinical and in some cases clinical data, to show that the new device is “substantially equivalent” to a similar product already on the market in safety and effectiveness. Because of the higher risk profile, extended wear CLs are class III devices and, as such, require premarket approval (PMA) before they can be marketed. The PMAs need to contain adequate preclinical and clinical assessments of these devices to provide reasonable assurance of safety and effectiveness. Since the first soft contact lens approval on March 18, 1971, CDRH has used many safeguards to assure the safety of CL and lens care products on the US market. Currently, FDA issues guidance documents to communicate its recommendations for preclinical and clinical testing of class II daily wear CLs and contact lens care products to CDRH staff, regulated industry, and the public. The first daily wear contact lens guidance was issued in 1994 to assist industry with the preparation of their premarket application submissions for FDA review. A guidance for contact lens care products was issued in 1997. In addition to guidance documents, FDA uses both national and international standards. FDA staff, along with industry and academia, participate in the development of both national and international standards through the American National Standards Institute and the International Organization for Standardization. Standards outline information needed for evaluation of a specific device, preclinical testing needed before human testing, and recommendations regarding clinical trial design. Declaration of conformity to standards recognized by the FDA can be used to meet premarket submission requirements. Over the years, the FDA has recognized several standards for both CLs and lens care products. The FDA assures that all CLs and contact lens care products have clear and detailed labeling to inform consumers of appropriate use and potential risks of these devices. Patient information labeling directed to the contact lens wearer includes information contained on the outside packaging, in the package insert, and on the primary container of the device. The patient labeling instructs the patient on appropriate product care to ensure lenses are used safely and effectively, informs the user of potential risks and benefits, and details of what to expect with the use of these products. To further emphasize the importance of appropriate contact lens care, the FDA has developed and maintained a consumer-focused website. All these safeguards have resulted in safe and effective CLs and care products. In fact, microbial keratitis is the most serious complication of CL wear, occurring at a rate of 4 to 20 cases per 10,000 CL wearers. Consequently, CLs have become one of the most commonly used medical devices on the market, with more than 40 million wearers in the United States. However, consumer confidence in the safety of CLs and their care products eroded in April of 2006 when 180 cases of Fusarium keratitis were reported in 36 states and US territories. This confidence was further undermined by an outbreak of Acanthamoeba keratitis in 2007. Both outbreaks were associated with the use of multipurpose solutions (MPSs) that had adequately satisfied the recommended antimicrobial premarket testing. As a result of these outbreaks, Bausch and Lomb’s ReNu with MoistureLoc MPS and AMO’s Complete MoisturePlus products were removed from the marketplace. From the Food and Drug Administration, Center for Devices and Radiological Health, Office of Device Evaluation, Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices, Silver Spring, MD. Supported by the Food and Drug Administration. Disclaimer: The mention of commercial products, their sources, or their use in connection with material reported here is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services. No conflicting relationship exists for any author. Address correspondence and reprint requests to Malvina B. Eydelman, M.D., 10903 New Hampshire Avenue, WO-66, Room 2410, Silver Spring, MD 20993; e-mail: malvina.eydelman@fda.hhs.gov. Accepted May 22, 2012.